Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT: NCT06192758 · ACTIVE_NOT_RECRUITING

NCT IDNCT06192758
StatusACTIVE_NOT_RECRUITING
Start Date2024-04-15
SponsorBoston Scientific Corporation (INDUSTRY)
First posted
Last updated

Brief Summary

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑